4 citations,
December 2021 in “Archivio italiano di urologia andrologia” Certain drugs, especially antiandrogens and spironolactone, significantly increase the risk of gynecomastia.
1 citations,
July 2023 in “Cureus” Some treatments for hereditary hair loss are effective but vary in results and side effects; new therapies show promise but need more research.
July 2024 in “Anais Brasileiros de Dermatologia” PRP injections can increase hair density in people with androgenic alopecia.
June 2024 in “Stem cell research & therapy” Regenerative medicine shows promise for treating skin disorders like hair loss and vitiligo.
January 2024 in “Journal of Cosmetic Dermatology” Microneedling combined with other treatments significantly improves hair growth in people with hair loss and is safe.
June 2020 in “Dermatologic therapy” Using Janus kinase inhibitors (JAKi) in COVID-19 treatment requires careful consideration due to their immunosuppressive effects.
April 2022 in “American Journal of Clinical Dermatology” 55 citations,
June 2007 in “Journal of Statistical Planning and Inference” The flexible fixed-sequence testing method allows for more effective evaluation of multiple goals in a clinical trial while controlling the risk of false positives.
25 citations,
November 2022 in “British journal of dermatology/British journal of dermatology, Supplement” Baricitinib for severe alopecia areata is generally safe, with common side effects like infections and acne, and low rates of serious complications.
24 citations,
March 2010 in “Value in Health” The PCOS-specific questionnaire needs more work to fully measure quality of life in clinical trials.
12 citations,
January 2003 in “Dermatology Online Journal” A new treatment for hair loss was tested and most participants saw their hair loss stop within 2-8 weeks, with up to 50% more hair after 4 months, and no side effects.
6 citations,
April 2004 in “Dermatologic Surgery” Finasteride showed limited hair growth and low patient compliance in treating male pattern baldness.
5 citations,
July 2019 in “Applied statistics/Journal of the Royal Statistical Society. Series C, Applied statistics” Case-only trees and random forests improve predictions of treatment effects in clinical trials.
April 2017 in “The journal of investigative dermatology/Journal of investigative dermatology” Researchers found three different ways drugs work to treat hair loss from alopecia areata and identified key factors for personalized treatment.
May 2004 in “Dermatologic Surgery” Most men stopped using finasteride for baldness due to unsatisfactory results or were lost to follow-up, and those who continued saw minimal to moderate improvement.
December 2022 in “Plastic and Reconstructive Surgery” PRP is an effective and safe treatment for hair loss.
October 2024 in “International Journal of Dermatology” Oral and topical minoxidil are equally effective for hair loss, but oral minoxidil causes more unwanted hair growth.
June 2024 in “Nature Cell and Science” The Scalp Coverage Scoring method reliably measures hair density from images.
February 2010 in “Journal of The American Academy of Dermatology” Ustekinumab significantly improved sexual function and quality of life for people with moderate to severe psoriasis.
2 citations,
July 2023 in “Journal of cosmetic dermatology” JAK inhibitors are more effective and safer for treating alopecia areata than dupilumab and apremilast.
September 2024 in “Journal of the American Academy of Dermatology” Baricitinib helps long-term hair regrowth in severe alopecia areata patients.
2 citations,
April 2018 in “Journal of Investigative Dermatology” The conclusion is that differentiating wound types in RDEB patients is important for clinical trials and understanding the disease.
1 citations,
June 2001 in “Annals of Internal Medicine” The conclusion is that maintaining blinding in clinical trials is crucial for reliable results.
211 citations,
November 1990 in “The Journal of Steroid Biochemistry and Molecular Biology” Finasteride effectively treats BPH, but needs more trials to understand potential.
3 citations,
March 2017 in “Regulatory toxicology and pharmacology” Aleglitazar and its major metabolite are safe enough to proceed to Phase 3 clinical trials.
April 2019 in “Biometrics” The new clinical trial design is promising but needs real-world trials to test its effectiveness and possible enhancements.
1 citations,
May 2003 in “The journal of investigative dermatology/Journal of investigative dermatology” A hormone affects hair growth, certain molecules may prevent skin damage, a skin disease is linked to immune cells, glycerol helps skin hydration, and psoriasis treatment trials need improvement.
June 2017 in “Experimental dermatology” Skin has a larger surface area than thought, certain skin cells improve skin flap survival, better trials for skin conditions in children are needed, Stevens-Johnson syndrome rates vary by age and race, and better skin barrier function may reduce inflammation in the elderly.
505 citations,
December 2011 in “Journal of clinical oncology” MK-2206 was safe and effectively blocked AKT signaling in cancer patients, warranting more trials.